Search
Ulcerative Colitis Paid Clinical Trials in District Of Columbia
A listing of 3 Ulcerative Colitis clinical trials in District Of Columbia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
The state of District Of Columbia currently has 3 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Washington, Washington, D.C., Washington DC and Washington, Dc.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Pediatric IBD Study
Recruiting
Is your 2-17 year old living with Crohn's Disease or Ulcerative Colitis? A clinical trial is currently open to enroll
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Colitis
Ulcerative
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Featured Trial
Ulcerative Colitis Clinical Trial
Recruiting
Are you or someone you know struggling with Ulcerative Colitis? A clinical study in the area is currently open to enroll participants. Eligible adults will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Ulcerative Colitis Chronic Mild
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Recruiting
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the M... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
05/23/2025
Locations: Emerson Clinical Research Institute ( Site 3820), Washington, District of Columbia
Conditions: Ulcerative Colitis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Ulcerative Colitis, Crohn Disease
1 - 3 of 3